| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 23rd November 2020 | Advisors Llc Perceptive | 500,000 | Open or private purchase | $12.85 | $6,425,000.00 |
| 27th October 2020 | Advisors Llc Perceptive | 3,000,000 | Open or private purchase | $10.00 | $30,000,000.00 |
| 21st October 2020 | Advisors Llc Perceptive | 43,195 | Open or private purchase | $10.09 | $435,837.55 |
| 20th October 2020 | Advisors Llc Perceptive | 114,100 | Open or private purchase | $10.00 | $1,141,000.00 |
| 22nd September 2020 | Advisors Llc Perceptive | 1,644,785 | Conversion of derivative | $0.00 | |
| 22nd September 2020 | Advisors Llc Perceptive | 1,058,824 | Open or private purchase | $17.00 | $18,000,008.00 |
| 15th September 2020 | Advisors Llc Perceptive | 2,911,764 | Open or private purchase | $4.25 | $12,374,997.00 |
| 14th September 2020 | Advisors Llc Perceptive | 400,000 | Open or private purchase | $40.00 | $16,000,000.00 |
| 14th September 2020 | Advisors Llc Perceptive | 1,800,000 | Open or private purchase | $11.00 | $19,800,000.00 |
| 10th September 2020 | Advisors Llc Perceptive | 200,000 | Open or private purchase | $11.24 | $2,248,000.00 |
Kadmon Holdings
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Kadmon Holdings, Inc. is a biopharmaceutical company. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir and Abacavir.
Ticker: KDMN
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1557142
Employees: 115
Exchange: New York Stock Exchange
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $170 M (0%)
Inventory, Net: $116 Th (0%)
Assets, Current: $185 M (0%)
Property, Plant and Equipment, Net: $2 M (0%)
Other Assets, Noncurrent: $22 Th (-78%)
Assets: $213 M (0%)
Accounts Payable, Current: $12 M (29%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $30 M (4%)
Liabilities: $50 M (1%)
Common Stock, Value, Issued: $171 Th (6%)
Common Stock, Shares, Issued: $171 M (7%)
Retained Earnings (Accumulated Deficit): $391 M (0%)
Stockholders' Equity (Parent): $163 M (-1%)
Liabilities and Equity: $213 M (0%)
Gross Margin: $336 Th (-94%)
Research and Development: $17 M (-43%)
Operating Income/Loss: $27 M (-37%)
Other Income, net: $232 Th (-98%)
EPS (basic): $0.17 (0%)
EPS (diluted): $0.17 (0%)
News
Tracking Dan Loeb's Third Point Portfolio - Q3 2020 Update
23rd November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
